A new paper by the Institute for Clinical and Economic Review (ICER) looks at the cost-effectiveness versus affordability issue of obesity medications such as Wegovy and Zepbound.

The U.S. does not buy drugs directly for a national health system, as countries such as England and Germany do, instead ...

WHEN COULD TRUMP ANNOUNCE PHARMA TARIFFS? Trump's executive order last week listed pharmaceuticals alongside lumber, semiconductors and other sectors that could be subject to investigation under ...

U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that ...

LifeMD's growth accelerates with expanded insurance, new health products, and a 43% revenue boost. Click here to read our ...

India’s obesity crisis fuels a $2.6 bn drug race as pharma firms rush to launch affordable semaglutide generics, aiming to ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...

Lawsuits against pharmacies in seven states aim to protect its flagship Mounjaro and Zepbound medications | Growing ...

Hims & Hers stirred the weight-loss waters by announcing it now offers prescriptions for Zepbound, Eli Lilly’s premium GLP-1 ...

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.